Immunocore Holdings plc

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Immunocore Holdings plc
Former names
Immunocore Ltd
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
United Kingdom
Headquarters city
Oxfordshire
Headquarters country
United Kingdom
Fiscal year end
December
Ticker symbol
IMCR
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001671927

Board of directors

Follow this board

Chief executives

Bahija Jallal · CHIEF EXECUTIVE OFFICER
Since January 2024

Board connections

5 of this board's directors also sit on 20 other boards.

Network of Immunocore Holdings plc's board connections ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals... ArriVent BioPharma Inc. ArriVent BioPharma Inc... BeOne Medicines Ltd. BeOne Medicines Ltd. Bicycle Therapeutics plc Bicycle Therapeutics p... DBV Technologies S.A. DBV Technologies S.A. Denali Therapeutics Inc. Denali Therapeutics In... Incyte Corp. Incyte Corp. Kiniksa Pharmaceuticals International plc Kiniksa Pharmaceutical... Kodiak Sciences Inc Kodiak Sciences Inc Kymera Therapeutics Inc. Kymera Therapeutics In... Madrigal Pharmaceuticals Inc. Madrigal Pharmaceutica... Neurogene Inc. Neurogene Inc. Prelude Therapeutics Incorporated Prelude Therapeutics I... Replimune Group Inc. Replimune Group Inc. TScan Therapeutics Inc. TScan Therapeutics Inc... vTv Therapeutics Inc. vTv Therapeutics Inc. Bahija Jallal Bahija Jallal Felix Baker Felix Baker Julian Baker Julian Baker Kristine Peterson Kristine Peterson Immunocore Holdings plc
Shared director Other board Same sector +4 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$7,813,937
11 sales by 4 insiders
Date Insider Transaction Shares Price Value
Feb 18, 2026 Bahija Jallal Director, Officer (CHIEF EXECUTIVE OFFICER) Open-market sale −11,474 $32.35 $371,184
Feb 18, 2026 GOLL JOHN Officer (SVP, FINANCE & CAO) Open-market sale −698 $32.35 $22,580
Feb 18, 2026 St Leger Tina Amber Officer (CHIEF HR OFFICER) Open-market sale −1,000 $32.35 $32,350
Feb 18, 2026 Berman David M Officer (HEAD OF R&D) Open-market sale −5,965 $32.35 $192,968
Feb 17, 2026 Bahija Jallal Director, Officer (CHIEF EXECUTIVE OFFICER) Option exercise +23,817 — —
Feb 17, 2026 GOLL JOHN Officer (SVP, FINANCE & CAO) Option exercise +1,351 — —
Feb 17, 2026 St Leger Tina Amber Officer (CHIEF HR OFFICER) Option exercise +2,119 — —
Feb 17, 2026 Berman David M Officer (HEAD OF R&D) Option exercise +11,824 — —
Dec 5, 2025 Berman David M Officer (HEAD OF R&D) Option exercise +572 $17.46 $9,987
Dec 5, 2025 Berman David M Officer (HEAD OF R&D) Open-market sale −572 $40.14 $22,960
Dec 4, 2025 Berman David M Officer (HEAD OF R&D) Option exercise +31,341 $17.46 $547,214
Dec 4, 2025 Berman David M Officer (HEAD OF R&D) Open-market sale −31,341 $40.26 $1,261,789
Nov 28, 2025 Berman David M Officer (HEAD OF R&D) Option exercise +5,521 $17.46 $96,397
Nov 28, 2025 Berman David M Officer (HEAD OF R&D) Open-market sale −5,521 $40.09 $221,337
Nov 26, 2025 Berman David M Officer (HEAD OF R&D) Option exercise +69,404 $17.46 $1,211,794

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.